Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [IR] Samsung Electronics (005930) – Q4 2025 Earnings Presentation / 2026-01-29 IR Room
  • [Research] SK hynix (000660 / SKHY) – DS Investment | Server Memory Demand · HBM3E Pricing · Margin Expansion / 2026-01-30 Research
  • [Research] Samsung Biologics (207940) – Hana Securities | Rockville Ramp-up · Business Scale Expansion · Revenue Visibility / 2026-07-24 Research
  • [Research] Hanwha Ocean (042660) – DS Investment & Securities | Merchant Vessel Profitability · High-Price Mix · MASGA Beneficiary / 2026-07-28 Research
  • [Research] Samsung SDI (006400) – DS Investment & Securities | Core Profitability Turnaround · Robust ESS Backlog · Humanoid Physical AI Expansion / 2026-07-31 Research
  • [Research] LIG D&A (079550) – Daishin Securities | 1Q26 Review · Earnings Surprise · Export Diversification / 2026-05-08 Research
  • [Research] Samsung Electro-Mechanics (009150) – IBK Securities | MLCC Price Hike · Supply Shortage · Earnings Acceleration / 2026-07-31 Research
  • [Research] Alteogen (196170) – Hana Securities | Exclusive Biogen Licensing Deal · ~USD 40M Q1 Cumulative Upfronts · Rich Q2 Catalysts Ahead / 2026-03-26 Research

[Research] LIG D&A (079550) – iM Securities | Export Pipeline · CapEx & Hiring Expansion · Global Air Defense Growth / 2026-08-07

Posted on August 7, 2026August 21, 2026 By ksb220805@gmail.com

Brokerage : iM Securities

Analyst : Yongjin Byun

Investment Rating : Buy (Maintain)

Target Price : KRW 1,230,000 (Maintain)

Core Momentum : Full-year OPM guidance raised to 8% overcoming 2Q base effects, supported by a KRW 24.6T order backlog, global pipeline expansion, and aggressive CapEx/R&D investments

1. [Valuation & Key Financial Metrics]

  • Investment Rating & Target Price: Rating Buy (Maintain), 12-Month Target Price KRW 1,230,000 (Maintain), Closing Price KRW 702,000 (As of 2026-08-06), Upside Potential 75.2%
  • Guidance & Forecast Revisions: Upward revision of annual corporate OPM guidance from 7% to 8% (iM Securities forecasts full-year OPM at 9.4%)
  • Financial Forecasts & Historicals (K-IFRS Consolidated):
    • 2023: Revenue KRW 4,307 Billion, Operating Profit KRW 319 Billion, Net Profit KRW 253 Billion, EPS KRW 11,516, BPS KRW 65,005, PER 36.6x, PBR 6.5x, ROE 19.2%, Dividend Yield 0.7%, EV/EBITDA 22.5x
    • 2024E: Revenue KRW 5,052 Billion, Operating Profit KRW 476 Billion, Net Profit KRW 359 Billion, EPS KRW 16,341, BPS KRW 78,122, PER 43.0x, PBR 9.0x, ROE 22.8%, Dividend Yield 0.4%, EV/EBITDA 24.8x
    • 2025E: Revenue KRW 6,037 Billion, Operating Profit KRW 589 Billion, Net Profit KRW 447 Billion, EPS KRW 20,298, BPS KRW 95,197, PER 34.6x, PBR 7.4x, ROE 23.4%, Dividend Yield 0.4%, EV/EBITDA 21.3x
    • 2026E: Revenue KRW 6,572 Billion, Operating Profit KRW 716 Billion, Net Profit KRW 549 Billion, EPS KRW 24,968, BPS KRW 116,942, PER 28.1x, PBR 6.0x, ROE 23.5%, Dividend Yield 0.4%, EV/EBITDA 18.5x
  • Stock Metrics: Capital Stock KRW 110 Billion, Outstanding Shares 22.0 Million shares, Market Cap KRW 15,444 Billion, Foreign Ownership 26.7%, 52-Week Range KRW 364,500 ~ KRW 1,020,000, 60-Day Avg Daily Volume 198,123 shares, 60-Day Avg Daily Trading Value KRW 164.7 Billion

2. [Market Opportunities & Business Outlook]

  • 2Q26 Earnings Review:
    • Consolidated revenue reached KRW 1,110.1 Billion and operating profit recorded KRW 105.7 Billion (OPM 9.5%), broadly meeting market consensus (KRW 1,164.6 Billion revenue, KRW 110.5 Billion operating profit).
    • Operating profit increased +29.5% YoY and OPM improved by +1.3%p YoY.
    • QoQ margin moderation (from 14.7% to 9.5%) was driven by base effects from 1Q accelerated deliveries, temporary lower UAE Cheongung shipments (KRW 99 Billion), and a reduced high-margin export revenue mix (from 34.7% to 25.4%).
  • Order Backlog & Global Pipeline Expansion:
    • Total order backlog stands at KRW 24.6 Trillion (including KRW 14 Trillion in exports, with KRW 9.9 Trillion from Middle Eastern contracts).
    • Growing interest in Cheongung-II procurement across Middle Eastern nations as well as Asia (Malaysia, Indonesia, Philippines), with high potential for contract conversion as defensive systems take priority over offensive weapons.
    • Pursuing a joint venture in Poland with domestic defense companies to explore Western European multi-layer air-defense opportunities.
  • Large-Scale CapEx & Workforce Expansion:
    • Total investments of over KRW 1.3 Trillion over the past three years (including planned amounts), such as Gumi facility expansions and Sejong R&D site acquisitions.
    • Workforce expanded by 69% between 2020 and 2025, leading global defense peers, with continuous hiring concentrated in high-level R&D talent.

Editor’s Comment (Perspective)

The covering analyst views LIG D&A not as an enterprise constrained by quarterly delivery base effects, but as a premier global defense contractor actively expanding its manufacturing footprint and elite R&D talent to absorb robust international demand. This perspective places primary importance on the upgraded full-year OPM guidance, broad pipeline expansion spanning Middle Eastern countries, Asia, and Western Europe (via the Polish joint venture initiative), and substantial CapEx investments (over KRW 1.3 Trillion) over short-term quarterly revenue variations.

To verify whether this investment thesis continues to materialize, primary focus should be directed toward the quarterly recovery pace of UAE Cheongung deliveries in 2H, the execution of new export contracts across Middle Eastern partners and Asia, and operational progress under the Polish joint venture initiative in Western Europe. These operational milestones can be monitored through upcoming quarterly earnings releases, corporate IR disclosures, contract award filings, and official periodic reports.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Defense

Post navigation

Previous Post: [Research] LIG D&A (079550) – Shinhan Securities | Structural Export Growth · Order Pipeline · Long-term Demand / 2026-08-07
Next Post: [Research] LIG D&A (079550) – Kiwoom Securities | Order Visibility · Production Expansion · Middle East Deliveries / 2026-08-07

Related Posts

  • [Research] Samsung SDI (006400) – Kiwoom Securities | ESS & BBU Momentum · Europe Market Share Recovery · 4Q26 Turnaround / 2026-04-29 Research
  • [Research] Samsung Biologics (207940) – Hana Securities | Rockville Ramp-up · Business Scale Expansion · Revenue Visibility / 2026-07-24 Research
  • [Research] Samsung Biologics (207940) – iM Securities | Spin-off Valuation Re-rating · Biosecure Act Inflows · Plant 6 Groundbreaking / 2026-01-09 Research
  • [Research] Samsung SDI (006400) – Shinhan Securities | North America ESS Surges · BBU Demand Expansion · Turnaround Visibility / 2026-04-20 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Memory Pricing · ADR Listing · Valuation Re-rating / 2026-03-23 Research
  • [Research] Celltrion (068270) – SK Securities | 2Q26 Re: Profitability Inflection Underway · Operating Leverage In Focus · Robust H2 Momentum / 2026-08-03 Research
  • [Research] Samsung Electro-Mechanics (009150) – Mirae Asset Securities | AI MLCC Shortage · FC-BGA Margin Expansion · Earnings Direction / 2026-07-31 Research
  • [Research] SK hynix (000660 / SKHY) – Shinhan | ADR Listing · HBM Pricing · Valuation Re-rating / 2026-06-30 Research
  • [Research] Alteogen (196170) – Shinhan Securities | Halozyme Patent Invalidated · Key Overhangs Materially Eased · Target Price Raised / 2026-05-14 Research
  • [Research] Samsung Biologics (207940) – IBK Securities | Plant 5 PPQ Revenue · US Site Consolidation · Guidance Revision Potential / 2026-04-23 Research
  • [Research] Celltrion (068270) – IBK Securities | New Biosimilar Mix Expansion · Operating Leverage · H2 Margin Expansion / 2026-05-07 Research
  • [Research] Samsung SDI (006400) – IBK Securities | Fully Booked North America ESS Expected · European IAA Benefits · 1Q Earnings Resilience / 2026-04-02 Research
  • [Research] Samsung SDI (006400) – DS Investment & Securities | Core Profitability Turnaround · Robust ESS Backlog · Humanoid Physical AI Expansion / 2026-07-31 Research
  • [Research] Hanwha Ocean (042660) – Yuanta | Merchant Mix Improvement · CPSP Project Value · MASGA Catalysts / 2026-07-06 Shipbuilding

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme